Free Trial

BioLife Solutions (BLFS) Competitors

$21.39
+0.37 (+1.76%)
(As of 01:31 PM ET)

BLFS vs. NTUS, INMD, AXGN, ZYXI, OM, PRCT, NARI, IRTC, CNMD, and NVCR

Should you be buying BioLife Solutions stock or one of its competitors? The main competitors of BioLife Solutions include Natus Medical (NTUS), InMode (INMD), AxoGen (AXGN), Zynex (ZYXI), Outset Medical (OM), PROCEPT BioRobotics (PRCT), Inari Medical (NARI), iRhythm Technologies (IRTC), CONMED (CNMD), and NovoCure (NVCR). These companies are all part of the "medical" sector.

BioLife Solutions vs.

Natus Medical (NASDAQ:NTUS) and BioLife Solutions (NASDAQ:BLFS) are both small-cap medical companies, but which is the better business? We will compare the two businesses based on the strength of their profitability, earnings, risk, valuation, institutional ownership, media sentiment, dividends, analyst recommendations and community ranking.

Natus Medical has higher revenue and earnings than BioLife Solutions. BioLife Solutions is trading at a lower price-to-earnings ratio than Natus Medical, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Natus Medical$473.44M2.41$13.18M$0.3789.08
BioLife Solutions$143.27M6.77-$66.43M-$1.42-14.82

Natus Medical has a net margin of 2.65% compared to Natus Medical's net margin of -45.84%. BioLife Solutions' return on equity of 10.15% beat Natus Medical's return on equity.

Company Net Margins Return on Equity Return on Assets
Natus Medical2.65% 10.15% 7.65%
BioLife Solutions -45.84%-12.89%-10.53%

BioLife Solutions received 178 more outperform votes than Natus Medical when rated by MarketBeat users. However, 82.12% of users gave Natus Medical an outperform vote while only 66.81% of users gave BioLife Solutions an outperform vote.

CompanyUnderperformOutperform
Natus MedicalOutperform Votes
124
82.12%
Underperform Votes
27
17.88%
BioLife SolutionsOutperform Votes
302
66.81%
Underperform Votes
150
33.19%

BioLife Solutions has a consensus price target of $23.83, suggesting a potential upside of 13.38%. Given Natus Medical's higher probable upside, analysts clearly believe BioLife Solutions is more favorable than Natus Medical.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Natus Medical
0 Sell rating(s)
0 Hold rating(s)
0 Buy rating(s)
0 Strong Buy rating(s)
N/A
BioLife Solutions
0 Sell rating(s)
0 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
3.00

92.4% of Natus Medical shares are owned by institutional investors. Comparatively, 93.2% of BioLife Solutions shares are owned by institutional investors. 1.2% of Natus Medical shares are owned by insiders. Comparatively, 2.2% of BioLife Solutions shares are owned by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Natus Medical has a beta of 0.22, suggesting that its share price is 78% less volatile than the S&P 500. Comparatively, BioLife Solutions has a beta of 1.85, suggesting that its share price is 85% more volatile than the S&P 500.

In the previous week, BioLife Solutions had 6 more articles in the media than Natus Medical. MarketBeat recorded 6 mentions for BioLife Solutions and 0 mentions for Natus Medical. Natus Medical's average media sentiment score of 1.06 beat BioLife Solutions' score of 0.59 indicating that BioLife Solutions is being referred to more favorably in the news media.

Company Overall Sentiment
Natus Medical Positive
BioLife Solutions Positive

Summary

BioLife Solutions beats Natus Medical on 9 of the 17 factors compared between the two stocks.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding BLFS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

BLFS vs. The Competition

MetricBioLife SolutionsElectromedical equipment IndustryMedical SectorNASDAQ Exchange
Market Cap$969.77M$2.99B$5.02B$8.47B
Dividend YieldN/A1.72%5.25%3.96%
P/E Ratio-14.825.69104.3814.28
Price / Sales6.7749.782,169.6081.98
Price / CashN/A73.1733.8733.62
Price / Book2.743.884.924.68
Net Income-$66.43M$83.47M$106.13M$214.30M
7 Day Performance1.20%12.40%117.18%3.36%
1 Month Performance0.24%7.69%128.87%9.33%
1 Year Performance4.88%-2.85%131.51%4.16%

BioLife Solutions Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
NTUS
Natus Medical
0 of 5 stars
0.00 / 5 stars
$32.96
flat
N/A+0.0%$1.14B$473.44M89.081,400
INMD
InMode
2.3067 of 5 stars
2.31 / 5 stars
$17.69
-1.4%
$30.80
+74.1%
-60.9%$1.49B$492.05M8.38581
AXGN
AxoGen
1.7343 of 5 stars
1.73 / 5 stars
$9.12
+1.7%
$12.25
+34.3%
+4.1%$398.59M$159.01M-18.24450
ZYXI
Zynex
3.1014 of 5 stars
3.10 / 5 stars
$10.10
-1.8%
$18.00
+78.2%
+10.1%$320.93M$188.68M43.911,100
OM
Outset Medical
1.5179 of 5 stars
1.52 / 5 stars
$3.87
-4.2%
$5.42
+40.0%
-79.9%$200.16M$130.38M-1.14520Gap Up
PRCT
PROCEPT BioRobotics
0.6828 of 5 stars
0.68 / 5 stars
$67.47
+1.1%
$62.60
-7.2%
+74.8%$3.47B$136.19M-31.83430
NARI
Inari Medical
2.4733 of 5 stars
2.47 / 5 stars
$54.90
+0.3%
$64.83
+18.1%
-4.5%$3.19B$493.63M-133.901,300Gap Down
IRTC
iRhythm Technologies
2.8941 of 5 stars
2.89 / 5 stars
$98.97
+0.5%
$130.88
+32.2%
-4.6%$3.08B$492.68M-23.402,000News Coverage
CNMD
CONMED
4.9864 of 5 stars
4.99 / 5 stars
$70.96
-0.9%
$102.50
+44.4%
-41.9%$2.19B$1.24B27.194,000Positive News
NVCR
NovoCure
3.4085 of 5 stars
3.41 / 5 stars
$18.40
-0.4%
$31.88
+73.2%
-52.7%$1.98B$509.34M-10.171,453Upcoming Earnings

Related Companies and Tools

This page (NASDAQ:BLFS) was last updated on 7/22/2024 by MarketBeat.com Staff

From Our Partners